Skip to main content
All lobbying clients

BOEHRINGER INGELHEIM USA CORPORATION

Lobbying client · Connecticut · filed 2025 to 2026

Pharmaceutical company

$7,085,000 Reported spend
24 Filings counted
3 Outside firms hired
13 Bills named

Spend is reported income plus in-house expenses across 24 filings. 2 further filings for this client were restated by a later amendment and are left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 4 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

 Who filed for this client 4

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 13
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    7 filings
  • S. 832
    EPIC Act of 2025
    7 filings
  • H.R. 8467
    Farm, Food, and National Security Act of 2024
    5 filings
  • H.R. 1842
    PAW Act of 2025
    5 filings
  • H.R. 7567
    Farm, Food, and National Security Act of 2026
    4 filings
  • H.R. 842
    Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
    4 filings
  • H.R. 946
    ORPHAN Cures Act
    4 filings
  • S. 1862
    ORPHAN Cures Act
    4 filings
  • S. 339
    Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
    4 filings
  • H.R. 3419
    Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2023
    3 filings
  • S. 1666
    Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2023
    3 filings
  • H.R. 5371
    Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and E…
    1 filing
  • H.R. 8646
    Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
    1 filing
 Reported by year 2 years
  • 2026 $3,145,000 12 filings
  • 2025 $3,940,000 12 filings
 Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 8
  • HOUSE OF REPRESENTATIVES 21
  • SENATE 21
  • Agriculture, Dept of (USDA) 14
  • Centers For Medicare and Medicaid Services (CMS) 9
  • Environmental Protection Agency (EPA) 7
  • Health & Human Services, Dept of (HHS) 2
  • Office of Management & Budget (OMB) 2
  • Food & Drug Administration (FDA) 1
 Recent filings 26 total
Q3 report
MONUMENT ADVOCACY
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $1,020,000 expenses · posted Oct 20, 2026
View →
Q3 report
MANATT, PHELPS, AND PHILLIPS
3rd Quarter 2026 (July 1 - Sep 30) · $20,000 income · posted Oct 19, 2026
View →
Q3 report
HANCE SCARBOROUGH
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 15, 2026
View →
Q2 report
MANATT, PHELPS, AND PHILLIPS
2nd Quarter 2026 (Apr 1 - June 30) · $20,000 income · posted Sep 29, 2026
View →
Registration
MANATT, PHELPS, AND PHILLIPS
2nd Quarter 2026 (Apr 1 - June 30) · posted Sep 22, 2026
View →
Q2 report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $710,000 expenses · posted Jul 20, 2026
View →
Q2 report
MONUMENT ADVOCACY
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
HANCE SCARBOROUGH
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 17, 2026
View →
Q1 report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $1,165,000 expenses · posted Apr 20, 2026
View →
Q1 report
MONUMENT ADVOCACY
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q1 report
HANCE SCARBOROUGH
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $20,000 income · posted Apr 18, 2026
View →
Q2 amendment
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $990,000 expenses · posted Mar 10, 2026
View →
Q4 amendment
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $610,000 expenses · posted Feb 4, 2026
View →
Q4 report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC Amended
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $580,000 expenses · posted Jan 20, 2026
View →
Q4 report
HANCE SCARBOROUGH
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $20,000 income · posted Jan 20, 2026
View →
Q4 report
MONUMENT ADVOCACY
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q3 report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $820,000 expenses · posted Oct 20, 2025
View →
Q3 report
MONUMENT ADVOCACY
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2025
View →
Q3 report
HANCE SCARBOROUGH
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 17, 2025
View →

Showing the 20 most recent of 26 filings. Search the explorer for "BOEHRINGER INGELHEIM USA CORPORATION".

 Foreign entities disclosed 1
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH Germany named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem